The NCI-MATCH trial: lessons for precision oncology

被引：60

作者：

O'Dwyer, Peter J. ^{[1
]}

Gray, Robert J. ^{[2
]}

Flaherty, Keith T. ^{[3
]}

Chen, Alice P. ^{[4
]}

Li, Shuli ^{[2
]}

Wang, Victoria ^{[2
]}

McShane, Lisa M. ^{[5
]}

Patton, David R. ^{[6
]}

Tricoli, James V. ^{[4
]}

Williams, P. Mickey ^{[7
]}

Iafrate, A. John ^{[3
]}

Sklar, Jeffrey ^{[8
]}

Mitchell, Edith P. ^{[9
]}

Takebe, Naoko ^{[4
]}

Sims, David J. ^{[7
]}

Coffey, Brent ^{[6
]}

Fu, Tony ^{[7
]}

Routbort, Mark ^{[10
]}

Rubinstein, Larry V. ^{[5
]}

Little, Richard F. ^{[4
]}

Arteaga, Carlos L. ^{[11
]}

Marinucci, Donna ^{[12
]}

Hamilton, Stanley R. ^{[13
]}

Conley, Barbara A. ^{[14
]}

Harris, Lyndsay N. ^{[14
]}

Doroshow, James H. ^{[4
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] ECOG ACRIN Biostat Ctr, Dana Farber Canc Inst, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[4] NCI, Div Canc Treatment & Diag, Bethesda, MD USA

[5] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA

[6] NCI, Ctr Biomed Informat & Informat Technol, Bethesda, MD USA

[7] Frederick Natl Lab Canc Res, Frederick, MD USA

[8] Yale Univ, New Haven, CT USA

[9] Thomas Jefferson Univ Hosp, Philadelphia, PA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] ECOG ACRIN Canc Res Grp, Philadelphia, PA USA

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] NCI, Canc Diag Program, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

NATURE MEDICINE | 2023年 / 29卷 / 6期

关键词：

PHASE-II; SOLID TUMORS; CANCERS; BRAF; VEMURAFENIB; INHIBITION; VALIDATION; TRAMETINIB; MUTATIONS; THERAPY;

D O I：

10.1038/s41591-023-02379-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The NCI-MATCH (Molecular Analysis for Therapy Choice) trial () was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.

引用

页码：1349 / 1357

页数：9

共 50 条

[41] Can Drug Repurposing Accelerate Precision Oncology?
Schipper, Luuk J.
Zeverijn, Laurien J.
Garnett, Mathew J.
Voest, Emile E.
CANCER DISCOVERY, 2022, 12 (07) : 1634 - 1641
[42] Precision oncology: separating the wheat from the chaff
Remon, Jordi
Dienstmann, Rodrigo
ESMO OPEN, 2018, 3 (06)
[43] Clonotyping for precision oncology
Dang, Ha X.
Maher, Christopher A.
DRUG DISCOVERY TODAY, 2015, 20 (12) : 1464 - 1469
[44] The Future of Precision Oncology
Rulten, Stuart L.
Grose, Richard P.
Gatz, Susanne A.
Jones, J. Louise
Cameron, Angus J. M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
[45] Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
Czauderna, Carolin
Kirstein, Martha M.
Tews, Hauke C.
Vogel, Arndt
Marquardt, Jens U.
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
[46] The Challenges of Precision Oncology Drug Development and Implementation
Hollingsworth, Simon J.
Biankin, Andrew V.
PUBLIC HEALTH GENOMICS, 2015, 18 (06) : 338 - 348
[47] Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience
Al Zoughbi, Wael
Kim, David
Alperstein, Susan Ann
Ohara, Kentaro
Manohar, Jyothi
Greco, Noah
Khani, Francesca
Robinson, Brian D.
Rao, Rema A.
Elemento, Olivier
Mosquera, Juan Miguel
Siddiqui, Momin T.
CANCER CYTOPATHOLOGY, 2021, 129 (11) : 874 - 883
[48] Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
Patel, Sandip P.
Schwaederle, Maria
Daniels, Gregory A.
Fanta, Paul T.
Schwab, Richard B.
Shimabukuro, Kelly A.
Kesari, Santosh
Piccioni, David E.
Bazhenova, Lyudmila A.
Helsten, Teresa L.
Lippman, Scott M.
Parker, Barbara A.
Kurzrock, Razelle
ONCOTARGET, 2015, 6 (32) : 32602 - 32609
[49] Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer
Borad, Mitesh J.
LoRusso, Patricia M.
MAYO CLINIC PROCEEDINGS, 2017, 92 (10) : 1583 - 1591
[50] The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development
Langenberg, Karin P. S.
Looze, Eleonora J.
Molenaar, Jan J.
CANCERS, 2021, 13 (17)

← 1 2 3 4 5 →